Please login to the form below

Not currently logged in
Email:
Password:

Prevenar 13

This page shows the latest Prevenar 13 news and features for those working in and with pharma, biotech and healthcare.

Global pledge to immunise 300 million children

Global pledge to immunise 300 million children

Pfizer later said it would it would cut the price of Prevenar 13 provided to certain developing nations by 6% and GSK committed to a 10-year price freeze for Synflorix.

Latest news

  • Pfizer's Prevenar 13 price cut slammed by MSF Pfizer's Prevenar 13 price cut slammed by MSF

    Pfizer's Prevenar 13 price cut slammed by MSF. Global health charity says reduction of 20 cents is "negligible". ... Pfizer has reduced the price of its pneumococcal vaccine Prevenar 13 for an immunisation programme targeting low-income countries, but

  • CHMP thumbs up for Novo's obesity drug Saxenda CHMP thumbs up for Novo's obesity drug Saxenda

    Prevenar 13 also backed. Meanwhile, the CHMP has also issued a positive opinion for an application by Pfizer to extend the indications for its pneumococcal vaccine Prevenar 13 to include the ... prevention of pneumonia caused by the 13 pneumococcal

  • Call for GSK and Pfizer to reduce vaccine price Call for GSK and Pfizer to reduce vaccine price

    The two leading vaccines in this area are Pfizer's Prevenar 13 and GSK's Synflorix, both of which are supplied to developing nations at a discount via the GAVI Alliance,

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    Moreover, if patients have already received one or more Pneumovax 23 shots the ACIP recommends they top up their protection with Prevnar 13. ... The ACIP decision comes shortly after European regulators started their review of Pfizer's vaccine - known as

  • Pfizer closes on $1bn label expansion for Prevenar Pfizer closes on $1bn label expansion for Prevenar

    European regulators have started their review of Pfizer's application to market pneumococcal vaccine Prevenar 13 more widely in adults, which could swell peak sales by $1bn or more. ... The results of the CAPiTA study underscore the potential benefits of

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics